ARHGAP39 was significantly decreased in 7 cancers: glioblastoma multiforme (GBM), pan-kidney cohort (KIPAN), kidney renal clear cell carcinoma (KIRC), thyroid carcinoma (THCA), testicular germ cell tumors (TGCT), adrenocortical carcinoma (ACC), and kidney chromophobe (KICH). This evidence concerns the gene ARHGAP39 and chromophobe renal cell carcinoma.